References of "PETROSSIANS, Patrick"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAdvances in diagnosis and management of familial pituitary adenomas
JEDIDI, Haroun ULg; ROSTOMYAN, Lilith; POTORAC, Iulia et al

in International Journal of Endocrine Oncology (in press)

Familial pituitary adenomas accounts for approximately 5-8 % of all pituitary adenomas. Besides the adenomas occurring as part of syndromic entities that bring together several endocrine or other systems ... [more ▼]

Familial pituitary adenomas accounts for approximately 5-8 % of all pituitary adenomas. Besides the adenomas occurring as part of syndromic entities that bring together several endocrine or other systems disorders, 2-3% of the familial pituitary adenomas fit into the familial isolated pituitary adenomas (FIPA) syndrome. 20% of FIPA syndromes have shown mutations in the AIP gene and have distinct clinical characteristics. Recent findings have isolated a new non-AIP FIPA syndrome called X-LAG, resulting from duplication in GPR-101 gene. These new advances in the field of pituitary disease are opening up a new challenging domain to both clinician and researcher. This review will focus on these last findings and their contribution to the diagnosis and the management of familial pituitary adenomas. [less ▲]

Detailed reference viewed: 121 (3 ULg)
Full Text
Peer Reviewed
See detailProspective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
VROONEN, Laurent ULg; Lancellotti, Patrizio ULg; Garcia, Monica Tome et al

in Endocrine (2016)

Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated ... [more ▼]

Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated in Parkinson's disease patients treated with dopamine agonists. Retrospective studies in prolactinoma patients treated with cabergoline at lower doses did not show such an effect. However, few prospective data with long-term follow-up are available. The aim of this study was to assess the safety of cabergoline regarding cardiac valvular status during prospective follow-up in patients treated for prolactinoma or idiopathic hyperprolactinemia. We report here a series of 100 patients (71F; median age at diagnosis: 41.5 years) treated with cabergoline for endocrine diseases (prolactinoma n = 89, idiopathic hyperprolactinemia n = 11). All patients underwent complete transthoracic echocardiographic studies at baseline and during long-term prospective surveillance using the same equipment and performed by the same technicians. The median interval between baseline and last follow-up echocardiographic studies while on cabergoline was 62.5 months (interquartile range: 34.75-77.0). The median total duration of cabergoline treatment was 124.5 months (interquartile range: 80.75-188.75) and the median cumulative total dose of cabergoline was 277.8 mg (interquartile range : 121.4-437.8 mg) at last follow-up. We found no clinically relevant alterations in cardiac valve function or valvular calcifications with cabergoline treatment. Our data suggest that findings from retrospective analyses are correct and that cabergoline is a safe chronic treatment at the doses used typically in endocrinology. [less ▲]

Detailed reference viewed: 13 (2 ULg)
Full Text
See detailThyroid nodule : metastasis or primary neoplasm ?
PETIGNOT, Sandrine ULg; PETROSSIANS, Patrick ULg; VAN DAELE, Daniel ULg et al

in 26nd meeting of the Belgian Endocrine Society - Abstract book (2016, October)

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailT2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.
Potorac, Iulia ULg; PETROSSIANS, Patrick ULg; Daly, Adrian ULg et al

in Endocrine-Related Cancer (2016), 23(11), 871881

GH-secreting pituitary adenomas can be hypo-, iso- or hyperintense on T2-weighted MRI sequences. We conducted the current multicenter study in a large population of patients with acromegaly to analyze the ... [more ▼]

GH-secreting pituitary adenomas can be hypo-, iso- or hyperintense on T2-weighted MRI sequences. We conducted the current multicenter study in a large population of patients with acromegaly to analyze the relationship between T2-weighted signal intensity on diagnostic MRI and hormonal and tumoral responses to somatostatin analogs (SSA) as primary monotherapy. Acromegaly patients receiving primary SSA for at least 3 months were included in the study. Hormonal, clinical and general MRI assessments were performed and assessed centrally. We included 120 patients with acromegaly. At diagnosis, 84, 17 and 19 tumors were T2-hypo-, iso- and hyperintense, respectively. SSA treatment duration, cumulative and mean monthly doses were similar in the three groups. Patients with T2-hypointense adenoma had median SSA-induced decreases in GH and IGF-1 of 88% and 59% respectively, which were significantly greater than the decreases observed in the T2-iso- and hyperintense groups (p<0.001). Tumor shrinkage on SSA was also significantly greater in the T2-hypointense group (38%) compared with the T2-iso- and hyperintense groups (8% and 3%, respectively; p<0.0001). The response to SSA correlated with the calculated T2-intensity: the lower the T2-weighted intensity, the greater the decrease of random GH (p<0.0001, r=0.22), IGF-1 (p<0.0001, r=0.14) and adenoma volume (p<0.0001, r=0.33). The T2-weighted signal intensity of GH-secreting adenomas at diagnosis correlates with the hormone reduction and tumor shrinkage in response to primary SSA treatment in acromegaly. This study supports its use as a generally available predictive tool at diagnosis that could help to guide subsequent treatment choices in acromegaly. [less ▲]

Detailed reference viewed: 26 (7 ULg)
Full Text
See detailHow T2-weighted signal intensity of GH-secreting adenomas correlates wit response to primary somatostatin analogue therapy in acromegaly
Potorac, Iulia ULg; PETROSSIANS, Patrick ULg; Daly, Adrian ULg et al

in Abstract book - 25th meeting of the Belgian Endocrine Society (2015, October)

Detailed reference viewed: 30 (6 ULg)
Full Text
See detailHyperparathyroïdie primaire familiale isolée - corrélation génotype - phénotype des mutations MEN 1?
Potorac, Iulia ULg; BETEA, Daniela ULg; PETROSSIANS, Patrick ULg et al

in Abstract book - Annales d'Endocrinologie - 32ème Congrès de la Société Française d'Endocrinologie (2015, October)

Detailed reference viewed: 37 (8 ULg)
Full Text
See detailExtension patterns in pituitary macroadenomas and relation to T2-weighted signal on diagnostic MRI examinations
Potorac, Iulia ULg; Cattin, F; KREUTZ, Julie ULg et al

in The International Journal of The Romania Society of Endocrinology - Abstract book (2015, June)

Detailed reference viewed: 30 (2 ULg)
Full Text
See detailDo T2-hypointense GH-secreting pituitary adenomas behave differently under somatostatin analogues as primary therapy in acromegaly ?
Potorac, Iulia ULg; PETROSSIANS, Patrick ULg; Daly, Adrian ULg et al

in The International Journal of The Romania Society of Endocrinology - Abstract book (2015, June)

Detailed reference viewed: 30 (3 ULg)
Full Text
See detailThe genetic causes of pituitary gigantism
Rostomyan, Liliya ULg; Daly, Adrian ULg; PETROSSIANS, Patrick ULg et al

in Endocrine Abstracts (2015, May)

Detailed reference viewed: 29 (6 ULg)
Full Text
Peer Reviewed
See detailIntérêt du signal T2 des adénomes hypophysaires à GH traités par analogues de la somatostatine - premiers résultats de l'étude IRMA#2
Potorac, Iulia ULg; PETROSSIANS, Patrick ULg; Daly, Adrian ULg et al

in Symposium "Perspectives in Endocrinology" - 5ème édition (2015, February 07)

Detailed reference viewed: 32 (3 ULg)
Full Text
Peer Reviewed
See detailX-linked acrogigantism (X-LAG) syndrome : Clinical Profile and Therapeutic responses
Beckers, Albert ULg; Lodish, MB; Trivellin, G et al

in Endocrine-Related Cancer (2015), 22

Detailed reference viewed: 32 (17 ULg)
Full Text
Peer Reviewed
See detailIntensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference.
KREUTZ, Julie ULg; VROONEN, Laurent ULg; Cattin, Françoise et al

in Neuroradiology (2015)

INTRODUCTION: Clinical presentations of prolactinomas are quite different between genders. In comparison with women's prolactinoma, those in men showed predominance of large tumors with high prolactin ... [more ▼]

INTRODUCTION: Clinical presentations of prolactinomas are quite different between genders. In comparison with women's prolactinoma, those in men showed predominance of large tumors with high prolactin (PRL) levels. This preponderance could be attributed to a greater proliferative potential of the tumors. Differences in magnetic resonance imaging (MRI) signal at diagnosis have not been yet clearly evaluated. METHODS: We conduct a retrospective study comparing MRI signal intensity (SI) on T2-weighted images (T2-WI) between 41 men and 41 women to investigate whether or not men prolactinoma present specific features. RESULTS: In addition to the size of the adenoma and PRL levels (P < 0001), prolactinomas in men also exhibit differences from those in women in signal on T2-WI on MRI (P < 0001). Women's prolactinomas are mostly of high SI on T2-WI while men's prolactinomas exhibit a more heterogeneous pattern of SI on T2-WI. Prolactinomas presenting with low SI on T2-WI are almost exclusively encountered in men. CONCLUSIONS: Presence of T2-WI hypointensities in pituitary adenoma can be predictive of a different subtype of prolactinoma almost encountered in men and possibly translate the presence of spherical amyloid deposits, in agreement with the literature. [less ▲]

Detailed reference viewed: 46 (9 ULg)
Full Text
Peer Reviewed
See detailVIEUX PHENOTYPE ET NOUVEAUX GENOTYPES Actualités dans le domaine des adénomes hypophysaires
GERARD, Caroline ULg; JEDIDI, Haroun ULg; PETROSSIANS, Patrick ULg et al

in Revue Médicale de Liège (2015), 70(11), 569-574

Gigantism and acromegaly, usually caused by a pituitary adenoma linked innapropriate secretion of growth hormon (GH) are generally considered as very rare diseases, even if, regarding some authors, their ... [more ▼]

Gigantism and acromegaly, usually caused by a pituitary adenoma linked innapropriate secretion of growth hormon (GH) are generally considered as very rare diseases, even if, regarding some authors, their cumulative prevalence is about 1/5000. Starting from the historical case of a giant from Liège we will describe the different types of GH pituitary adenomas and their physiopathology. We will overall discuss rare forms of inherited GH secreting pituitary adenomas like the FIPA (familial inherited isolated pituitary adenomas) and the X-LAG (X linked acrogigantism), both described in Liège, respectively in 2000 and 2014. [less ▲]

Detailed reference viewed: 69 (18 ULg)
Full Text
Peer Reviewed
See detailClinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients.
Rostomyan, Liliya ULg; Daly, Adrian ULg; PETROSSIANS, Patrick ULg et al

in Endocrine-related cancer (2015)

Despite being a classical growth disorder, pituitary gigantism has not been studied previously in a standardized way. We performed a retrospective, multicenter, international study to characterize a large ... [more ▼]

Despite being a classical growth disorder, pituitary gigantism has not been studied previously in a standardized way. We performed a retrospective, multicenter, international study to characterize a large series of pituitary gigantism patients. We included 208 patients (163 males; 78.4%) with growth hormone excess and current/previous abnormal growth velocity for age or final height >2SD above country normal means. The median onset of rapid growth was 13.0 years and occurred significantly earlier in females than in males; pituitary adenomas were diagnosed earlier in females than males (15.8 vs. 21.5 years, respectively). Adenomas were >/=10 mm (i.e. macroadenomas) in 84%, of which extrasellar extension occurred in 77% and invasion in 54%. GH/IGF-1 control was achieved in 39% during long-term follow-up. Final height was greater in those with younger age of onset, with larger tumors and higher GH levels. Later disease control was associated with a greater difference from mid-parental height (r=0.23, P=0.02). AIP mutations occurred in 29%; microduplication at Xq26.3 -X-linked acro-gigantism (X-LAG)- occurred in two familial isolated pituitary adenoma (FIPA) kindreds and in ten sporadic patients. Tumor size was not different in X-LAG, AIP mutated and genetically-negative patient groups. AIP-mutated and X-LAG patients had significantly younger age at onset and diagnosis, but disease control was worse in genetically-negative cases. Pituitary gigantism patients are characterized by male predominance and large tumors that are difficult to control. Treatment delay increases final height and symptom burden. AIP mutations and X-LAG explain many cases, but no genetic etiology is seen in >50% of cases. [less ▲]

Detailed reference viewed: 57 (17 ULg)
See detailEchographie de la Thyroïde
PETROSSIANS, Patrick ULg; PETIGNOT, Sandrine ULg; Benoit, Arnaud ULg et al

Book published by Graphmed SPRL (2015)

Detailed reference viewed: 32 (2 ULg)
Full Text
Peer Reviewed
See detailPituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences.
Potorac, Iulia ULg; PETROSSIANS, Patrick ULg; Daly, Adrian ULg et al

in Endocrine-related cancer (2015)

Context: Responses of GH-secreting adenomas to multimodal management of acromegaly varies widely between patients. Understanding the behavioral patterns of GH-secreting adenomas by identifying predictive ... [more ▼]

Context: Responses of GH-secreting adenomas to multimodal management of acromegaly varies widely between patients. Understanding the behavioral patterns of GH-secreting adenomas by identifying predictive factors of their evolution is a research priority. Objective: To clarify the relationship between adenoma T2-weighted signal on diagnostic MRI in acromegaly and clinical and biological features at diagnosis. Design: International, multicenter, retrospective analysis. Setting: 10 endocrine tertiary referral centers. Patients: 297 acromegalic recently diagnosed patients with available diagnostic MRI evaluations were included in the study. Main outcome measure: Clinical, biochemical characteristics and MRI signal findings. Results: T2-hypointense adenomas represented 52.9% of the series, were smaller than their T2-hyper- and isointense counterparts (p<0.0001), were associated with higher IGF1 levels (p=0.0001), invaded the cavernous sinus less frequently (p=0.0002) and rarely caused optic chiasm compression (p<0.0001). Acromegalic men tended to be younger at diagnosis than women (p=0.067) and presented higher IGF1 values (p=0.01). Although in total, adenomas had a predominantly inferior extension in 45.8% of cases, in men this was more frequent (p<0.0001), whereas in women optic chiasm compression of macroadenomas occurred more often (p=0.0067). Most adenomas (45.1%) measured between 11-20mm in maximal diameter and bigger adenomas were diagnosed at younger ages (p=0.0001). Conclusions: T2-weighted signal differentiates GH-secreting adenomas into subgroups with particular behaviors. This raises the question of whether T2-weighted signal could represent a factor in the classification of acromegalic patients in future studies. [less ▲]

Detailed reference viewed: 55 (9 ULg)
Full Text
See detailCharacterization of paragangliomas : a single center cohort study
VROONEN, Laurent ULg; Maiga, Ibrahima ULg; PETROSSIANS, Patrick ULg et al

in Abstract book - 24th Meeting of the Belgian Endocrine Society (2014, October 18)

Detailed reference viewed: 27 (8 ULg)